Poison Pill

A poison pill is a shareholder rights plan that a company’s board of directors can adopt to prevent a hostile takeover. When an acquirer accumulates shares above a threshold (typically 15–20% of outstanding), the rights plan is triggered and existing shareholders receive the right to buy additional shares at a steep discount, massively diluting the acquirer’s stake and making the acquisition economically unviable. Poison pills are now nearly universal among large public companies and have fundamentally altered the landscape of hostile takeovers.

How a poison pill works

A poison pill is a contract right attached to each share of the company. The rights plan is typically adopted by the board of directors without a shareholder vote (though shareholders can later ratify or reject it).

The trigger: If an acquirer accumulates shares above a specified threshold — commonly 15–20% of outstanding shares — the rights become exercisable.

The consequence: Existing shareholders (other than the acquirer) gain the right to buy additional shares at a heavily discounted price, typically 50% of the current market price. If shareholders exercise this right, the acquirer’s ownership percentage is massively diluted.

Simple example: Suppose a company has 100 million shares outstanding at $50 per share. The board adopts a poison pill with a 15% trigger. An acquirer accumulates 20 million shares (20%) and triggers the pill. Existing shareholders (who own 80 million shares) now have the right to buy 80 million additional shares at $25 per share. If they exercise, there are now 180 million shares outstanding, and the acquirer’s 20 million shares represent only 11% of the company — a massive dilution. The acquirer would need to spend an additional $2 billion to restore its ownership stake.

This economic penalty makes the hostile takeover unviable: the acquirer would have to pay far more to acquire the company than it would be worth.

Variations: flip-in and flip-over

Flip-in rights are the most common form, as described above. Shareholders other than the acquirer can buy shares at a discount.

Flip-over rights are activated upon a merger: if the company is acquired and merged into another entity, the shareholders of the acquired company gain the right to buy shares of the acquirer at a steep discount. This is less punitive than a flip-in (the acquirer may have already acquired control via a tender offer) but it still increases the cost of the deal.

Some poison pills combine both mechanisms for added protection.

The development of the poison pill

The poison pill was invented by Martin Lipton, a prominent M&A lawyer, in 1982. It was a breakthrough in takeover defence. Before the poison pill, hostile takeovers were relatively uncommon but feasible — an acquirer could launch a tender offer, accumulate shares, and with adequate pricing, force the shareholders’ hand.

Poison pills changed the calculus. Suddenly, a hostile bidder could not simply outbid on price; it had to overcome the dilution mechanism. The only way around a poison pill was to:

1. Negotiate with the board and get them to redeem the pill.
2. Win a proxy fight to elect a new board that would redeem the pill.
3. Make a tender offer so attractive that shareholders accepted it and elected a new board to redeem the pill.

As poison pills became standard (adopted by 80%+ of large public companies by the 1990s), hostile takeovers became much rarer. The threat of a poison pill eliminates many potential hostile bids before they are even announced.

Legal status and challenges

Poison pills have been challenged in court numerous times, but the Delaware courts — the governing authority for most large US corporations — have generally upheld them as valid. The key cases:

Moran v. Household International (1985). Delaware’s Supreme Court upheld poison pills, holding that they are a permissible form of takeover defence available to boards seeking to protect shareholders from coercive offers.

Revlon v. MacAndrews & Forbes (1986). Delaware held that once a board has decided to sell the company, it must conduct an active auction and cannot use defensive tactics to block higher bids.

Over time, Delaware courts have held that a poison pill is permissible only if the board is genuinely protecting shareholder interests, not entrench itself. Courts scrutinize boards that adopt poison pills to ensure they are not simply protecting their own jobs or avoiding accountability.

Redemption and negotiation

If a poison pill is triggered, the board has the power to redeem it — to cancel the shareholders’ rights and remove the dilution threat. This gives the board leverage in negotiations with a hostile bidder: “We will redeem the pill if you raise your offer to $X” or “if you negotiate in good faith.”

Conversely, a new board elected through a proxy fight will typically redeem the pill immediately, allowing the acquirer’s offer to proceed.

Modern criticism and reform

In recent years, poison pills have come under criticism from shareholder advocates and some activists who argue that:

• Poison pills entrench management and prevent shareholders from evaluating hostile bids
• The 15–20% threshold is often too low, preventing activists from building a meaningful stake
• In an era of strong corporate governance and active boards, poison pills may be unnecessary

Some shareholder activists have pushed for companies to redeem poison pills or to link pill triggers to constructive engagement (e.g., the pill is redeemed if the acquirer agrees to negotiate with the board for a specified period).

However, most boards have retained poison pills, and they remain one of the most effective — and controversial — takeover defences.

See also